Table 1. Baseline demographics.
| Placebo (N=33) | Active (N=33) | All (N=66) | |
|---|---|---|---|
| Gender (n) | |||
| Girls | 16 | 16 | 32 |
| Boys | 17 | 17 | 34 |
| Age (years)a | 5.0 (0.7) | 4.9 (0.8) | 5.0 (0.9) |
| Girls | 4.9 (0.8) | 4.8 (0.9) | 4.8 (0.8) |
| Boys | 5.2 (0.6) | 5.0 (0.8) | 5.1 (0.7) |
| BMI (kg/m2)a | 15.6 (2.5) | 15.5 (2.2) | 15.5 (2.3) |
| Girls | 15.3 (2.0) | 15.8 (2.4) | 15.5 (2.2) |
| Boys | 15.9 (2.9) | 15.2 (2.0) | 15.5 (2.5) |
| Centre, n (%) | |||
| Centre 1 | 21 (63.6) | 21 (63.6) | 42 (63.6) |
| Centre 2 | 6 (18.2) | 6 (18.2) | 12 (18.2) |
| Centre 3 | 6 (18.2) | 6 (18.2) | 12 (18.2) |
| Eczema, n (%) | 5 (15.2) | 2 (6.1) | 7 (10.6) |
| Atopic disease,b n (%) | 4 (12.1) | 2 (6.1) | 6 (9.1) |
| Food allergy, n (%) | 3 (9.1) | 0 (0) | 3 (4.5) |
| Coeliac disease, n (%) | 0 (0) | 1 (3.0) | 1 (1.5) |
Abbreviation: BMI, Body Mass Index.
a
Data are presented as mean (s.d.), intention to treat analysis.
b
Allergic rhinitis, atopic eczema or asthma.